Results 61 to 70 of about 59,711 (283)

Preclinical evaluation of [18F]SYN1 and [18F]SYN2, novel radiotracers for PET myocardial perfusion imaging [PDF]

open access: yes
BACKGROUND: Positron emission tomography (PET) is now an established diagnostic method for myocardial perfusion imaging (MPI) in coronary artery disease, which is the main cause of death globally. The available tracers show several limitations, therefore,
Łyczko, Krzysztof   +13 more
core   +1 more source

PET Imaging of Monoamine Oxidase B

open access: yes, 2020
The monoamine oxidase B (MAO-B) enzyme has a prominent role in brain function, being involved in the breakdown of monoaminergic neurotransmitters. Abnormally high MAO-B levels in the brain, found across different neurological and neurodegenerative ...
Rodriguez-Vieitez, E   +1 more
core   +1 more source

Gut microbiome and aging—A dynamic interplay of microbes, metabolites, and the immune system

open access: yesFEBS Letters, EarlyView.
Age‐dependent shifts in microbial communities engender shifts in microbial metabolite profiles. These in turn drive shifts in barrier surface permeability of the gut and brain and induce immune activation. When paired with preexisting age‐related chronic inflammation this increases the risk of neuroinflammation and neurodegenerative diseases.
Aaron Mehl, Eran Blacher
wiley   +1 more source

Role of Positron Emission Tomography Cardiac Perfusion Imaging in Clinical Management, Prognosis, and Risk Stratification of Cardiovascular Disease

open access: yesIndian Journal of Clinical Cardiology, 2023
Coronary artery disease (CAD) is an important cause of morbidity and mortality worldwide. Perfusion abnormalities precede wall motion abnormalities, ECG changes, and angina in the etiology of CAD.
Vijay Singh   +5 more
doaj   +1 more source

Evaluation of the Genisys4, a Bench-Top Preclinical PET Scanner [PDF]

open access: yesJournal of Nuclear Medicine, 2013
The Genisys4 is a small bench-top preclinical PET scanner designed to enable imaging in biology, biochemistry, and pharmacology laboratories and imaging centers. Here, we compare its performance with that of a well-established preclinical PET scanner.Subcutaneous and lung tumor xenografts were used to compare lesion detectability and treatment ...
Ken, Herrmann   +6 more
openaire   +2 more sources

Design and analysis strategies for robust microbiome ageing research

open access: yesFEBS Letters, EarlyView.
The gut microbiome changes with age and associates with age‐related morbidity and mortality, establishing it as a potential biomarker and intervention target for ageing. Realising this potential requires methodological rigour, yet distinguishing biological signals from methodological artefacts remains challenging across cohorts. This review provides an
Mark Olenik   +5 more
wiley   +1 more source

Evaluation of bone marrow glucose uptake and adiposity in male rats after diet and exercise interventions

open access: yesFrontiers in Endocrinology
ObjectivesObesity impairs bone marrow (BM) glucose metabolism. Adult BM constitutes mostly of adipocytes that respond to changes in energy metabolism by modulating their morphology and number. Here we evaluated whether diet or exercise intervention could
Ronja Ojala   +15 more
doaj   +1 more source

18F-FDG-PET in Mouse Models of Alzheimer's Disease

open access: yesFrontiers in Medicine, 2019
Suitable animal models and in vivo biomarkers are essential for development and evaluation of new therapeutic strategies in Alzheimer's disease (AD). 18F-Fluorodeoxyglucose (18F-FDG)-positron-emission tomography (PET) is an imaging biomarker that allows ...
Caroline Bouter, Yvonne Bouter
doaj   +1 more source

Radiopharmaceuticals in Preclinical and Clinical Development for Monitoring of Therapy with PET [PDF]

open access: yesJournal of Nuclear Medicine, 2009
This review article discusses PET agents, other than (18)F-FDG, with the potential to monitor the response to therapy before, during, or after therapeutic intervention. This review deals primarily with non-(18)F-FDG PET tracers that are in the final stages of preclinical development or in the early stages of clinical application for monitoring the ...
Mark P S, Dunphy, Jason S, Lewis
openaire   +2 more sources

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

open access: yesMolecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy